Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Molecular Pathway Decreases Cell Adhesion and Initiates Metastasis

By BiotechDaily International staff writers
Posted on 28 Jul 2014
A recent paper outlined a molecular pathway that enables lung cancer cells to migrate away from the site of the primary tumor and become established in other parts of the body.

Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) linked a virtual alphabet soup of genes and their protein products to the epithelial-to-mesenchymal transition (EMT) that is a prerequisite for metastasis.

The serine/threonine kinase LKB1 (liver kinase B1) is a tumor suppressor gene whose loss is associated with increased metastatic potential. In an effort to define biochemical signatures of metastasis associated with LKB1 loss, the investigators discovered that the EMT transcription factor Snail1 was uniquely upregulated upon LKB1 deficiency across cell types. Snail1 is a central regulator of epithelial cell adhesion and movement in EMTs during embryo development; a process reactivated during cancer metastasis. The ability of LKB1 to suppress Snail1 levels was independent of AMPK (AMP-activated protein kinase) but required the related kinases MARK1 (MAP/microtubule affinity-regulating kinase 1) and MARK4 (MAP/microtubule affinity-regulating kinase 4).

In a screen for substrates of the kinases involved in Snail regulation, the investigators identified the scaffolding protein DIXDC1 (DIX domain containing 1), a positive regulator of the Wnt signaling pathway that is associated with gamma tubulin at the centrosome. Similar to loss of LKB1, DIXDC1 depletion resulted in upregulation of Snail1 in a FAK (Focal Adhesion Kinase)-dependent manner, leading to increased cell invasion. FAK is a focal adhesion-associated protein kinase involved in cellular adhesion and spreading processes. It has been shown that when FAK was blocked, breast cancer cells became less metastatic due to decreased mobility.

MARK1 phosphorylation of DIXDC1 was required for its localization to focal adhesions and ability to suppress metastasis in mice. DIXDC1 is frequently downregulated in human cancers, which correlates with poor survival.

"Lung cancer, even when it is discovered early, is often able to metastasize almost immediately and take hold throughout the body," said senior author Dr. Reuben J. Shaw, professor of molecular and cell biology at the Salk Institute for Biological Studies. "The reason behind why some tumors do that and others do not has not been very well understood. Now, through this work, we are beginning to understand why some subsets of lung cancer are so invasive. The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early-stage clinical trials."

The study was published in the July 17, 2014, online edition of the journal Molecular Cell.

Related Links:

Salk Institute for Biological Studies



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.